International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform

The International Cancer Genome Consortium (ICGC) is further enabling cancer research worldwide by making a massive collection of cancer data available for analysis via Microsoft's Azure cloud computing platform. Providing secure, controlled access to ICGC genomic and clinical data on Azure will mitigate the need for researchers to obtain massive amounts of storage and computing power within their home institutions, meaning that more researchers will be able to use the data. The use of Azure was made possible by a philanthropic grant from Microsoft’s AI for Health program.

ICGC is a global collaboration that has generated comprehensive datasets of genomic mutations in more than 50 cancer types and made them available to researchers around the world to accelerate the development of next generation cancer treatments and diagnostics. The use of Azure will advance these efforts by providing cloud-based storage of ICGC data as well as a virtual computing platform to allow researchers to conduct data analysis in the cloud, using Azure-stored data or that from other ICGC platforms. Seven-hundred-fifty-four terabytes of ICGC data are available on Azure, comprising more than 75,000 files from 3,000 patient donors across 15 different cancer types.

"Through Azure we will put ICGC data into the hands of more scientists and remove the constraints that come with working with these large datasets. For example, even when using a high-speed internet connection, it can take researchers months to download the data they need. With Azure we've done away with that hurdle completely by taking the researcher's query to the data in the cloud," says Dr. Lincoln Stein, Head, Adaptive Oncology, Ontario Institute for Cancer Research and leader of the ICGC Data Coordination Center. "We are thankful for Microsoft's support and are grateful to the thousands of patients who donated the samples behind the data. We look forward to seeing the discoveries made using this new platform for ICGC data that will ultimately improve the lives of cancer patients."

"Cloud computing has the power to bring together researchers all over the world and advance scientific discoveries," says Geralyn Miller, Senior Director, Health Strategy, Microsoft AI for Good Research Lab. "The ICGC project is instrumental in the future of cancer research, and we are proud to help improve access to data for the global cancer research community through the AI for Health program."

ICGC has now moved into its next phase called ICGC ARGO (Accelerating Research in Genomic Oncology). ICGC ARGO will uniformly analyze specimens from 100,000 cancer patients with high quality clinical data to address outstanding questions that are vital to our quest to defeat cancer. It is anticipated that the Azure platform will be used to bring this incredibly valuable resource to the global cancer research community.

About the Ontario Institute for Cancer Research

OICR is a collaborative, not-for-profit research institute funded by the Government of Ontario. We conduct and enable high-impact translational cancer research to accelerate the development of discoveries for patients around the world while maximizing the economic benefit of this research for the people of Ontario. For more information visit http://www.oicr.on.ca.

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Blocking enzyme could hold the key to preventing, …

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

GSK to acquire clinical-stage biopharmaceutical co…

GSK plc (LSE/NYSE: GSK) announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...